Literature DB >> 26405697

Infliximab Therapy for Corticosteroid-Resistant Ipilimumab-Induced Colitis.

Poonam Beniwal-Patel1, Kristina Matkowskyj2, Freddy Caldera3.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 26405697     DOI： 10.15403/jgld.2014.1121.243.bwp

Source DB:  PubMed          Journal:  J Gastrointestin Liver Dis        ISSN： 1841-8724            Impact factor:   2.008


× No keyword cloud information.
  4 in total

1.  Systematic review and case series: flexible sigmoidoscopy identifies most cases of checkpoint inhibitor-induced colitis.

Authors:  Andrew P Wright; Marc S Piper; Shrinivas Bishu; Ryan W Stidham
Journal:  Aliment Pharmacol Ther       Date:  2019-04-29       Impact factor: 8.171

2.  Severe Gastritis after Administration of Nivolumab and Ipilimumab.

Authors:  Yoshito Nishimura; Miho Yasuda; Kazuki Ocho; Masaya Iwamuro; Osamu Yamasaki; Takehiro Tanaka; Fumio Otsuka
Journal:  Case Rep Oncol       Date:  2018-08-17

3.  Immune-mediated Colitis from Dual Checkpoint Inhibitors.

Authors:  Nishanth Thalambedu; Yasir Khan; Qian Zhang; Shristi Khanal; Ammar Ashfaq
Journal:  Cureus       Date:  2019-11-26

Review 4.  Clinical Characteristics and Treatment of Immune-Related Adverse Events of Immune Checkpoint Inhibitors.

Authors:  Juwhan Choi; Sung Yong Lee
Journal:  Immune Netw       Date:  2020-02-17       Impact factor: 6.303
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.